Rochester, NY 7/3/2009 11:40:11 PM
Market Update - MYRX - Public Conference to be Hosted by Myriad Pharmaceuticals - Sourced WhisperFromWallStreet.com
Myriad Pharmaceuticals, Inc.
Market Update - MYRX - Public Conference to be Hosted by Myriad Pharmaceuticals - Sourced WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert. We have sent out 40 alerts so far in 2009 with an average price gain of over 80%. Please join risk free and see for yourself.
Sign up for our FREE alerts at WhisperfromWallStreet.com
-----
Myriad Pharmaceuticals, Inc.,MYRX
Myriad Pharmaceuticals, Inc. (Nasdaq:MYRXV) today announced that it will hold a live webcast on Wednesday, July 1, 2009 at 10:00 AM EDT. Adrian Hobden, Ph.D., the Company's President and Chief Executive Officer will provide an overview of the Company's corporate strategy and pipeline of novel small molecule drug candidates to treat severe medical conditions, including cancer and HIV infection. Myriad Pharmaceuticals is a wholly owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN). Myriad Pharmaceuticals expects to complete its spin-off from Myriad Genetics, Inc. on June 30, 2009 and be an independent company on July 1, 2009. Myriad Pharmaceuticals' common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading on July 1, 2009 under the symbol "MYRX". Until the Company begins trading on the NASDAQ Global Market, Myriad Pharmaceuticals is trading under the symbol "MYRXV", denoting its "when-issued" trading status.
About
Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of therapeutic drug candidates. The companys activities include identification of drug targets, discovery of molecules, development of drug candidates, and design and execution of clinical programs. It develops four drug candidates that involve in human clinical trials, as well as engages in the research and development of cancer and infectious disease drugs. The company was founded in 1998 and is based in Salt Lake City, Utah. Myriad Pharmaceuticals, Inc. operates as a subsidiary of Myriad Genetics, Inc.
Last Trade: 4.16
Day's Range: 3.81 - 4.32
52wk Range: N/A
Volume: 1,866,994
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
